SCHEMBL4569803

SCHEMBL4569803

N=C(N)NCCC[C@H](NC(=O)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NRP1 O14786 2/20 0.51
POLB P06746 1/20 0.45
HTR6 P50406 1/20 0.42
PFKFB3 Q16875 1/20 0.42
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
THRB P10828 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
C3AR1 Q16581 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.39
LMNA P02545 1/20 0.39
ATIC P31939 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3696198 0.92 NRP1 (0.45) NRP1POLBHTR6MEN1KMT2A
SCHEMBL4572247 0.87 NRP1 (0.50) NRP1POLBHTR6PFKFB3HDAC2
SCHEMBL4569806 0.84 DDX3X (0.45) HDAC2HDAC8HDAC6C3AR1
SCHEMBL4569796 0.84 NRP1 (0.55) NRP1POLBGAAMEN1KMT2A
SCHEMBL3711157 0.82 NRP1 (0.74) NRP1
SCHEMBL4569797 0.81 NRP1 (0.54) NRP1POLBHDAC2HDAC8HDAC6
SCHEMBL4572260 0.79 ATIC (0.46) NRP1POLBHTR6MEN1KMT2A
SCHEMBL4569800 0.78 NRP1 (0.49) NRP1C3AR1LMNA
SCHEMBL7925397 0.77 C3AR1 (0.52) C3AR1
SCHEMBL188590 0.77 C3AR1 (0.52) C3AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2012-10-25 US disclosed
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed
US-8158789-B2 Arginine derivatives with NP-I antagonistic activity Ark Therapeutics Group Ltd. (GB) 2012-04-17 US disclosed
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 NRP1 145/4885POLB 4685/4885HTR6 2001/4885
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 NRP1 145/4885POLB 4685/4885HTR6 2001/4885
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 NRP1 145/4885POLB 4685/4885HTR6 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.